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unitermosresumo
Introdução: Osteossarcoma é uma neoplasia rara do tecido ósseo, tendo sido publicados poucos trabalhos na 
literatura que avaliaram o índice de proliferação celular Ki-67 (IPC-Ki-67) nesse tipo de sarcoma. Objetivo: 
Avaliação e comparação dos parâmetros clínicos, histológicos e de imunoexpressão do Ki-67 com a evolução 
clínica dos pacientes. Material e método: Blocos de parafina de 57 casos de osteossarcomas, cujos pacientes 
apresentavam dados clinicopatológicos fidedignos, foram submetidos a estudo da proliferação celular através 
da técnica de imuno-histoquímica. Em cada amostra o IPC foi determinado pela contagem de núcleos marca-
dos em pelo menos mil células neoplásicas. Em cada grupo de pacientes o IPC-Ki-67 foi considerado alto ou 
baixo, tendo como referência a mediana dos valores do Ki-67. Resultados e discussão: Não houve correlação 
estatística significativa entre os valores do IPC-Ki-67 (valor de corte = 45%) dos osteossarcomas dos pacientes 
com ou sem metástases ao diagnóstico, em relação às variáveis óbito, recaída tumoral, tamanho do tumor e 
tipo de cirurgia. No grupo de pacientes sem metástases houve correlação direta entre o tempo de sobrevida 
e o índice de proliferação celular (isto é, o IPC-Ki-67 > 45% correlacionou-se com maior tempo de sobrevida). 
Nos casos de pacientes com metástases ao diagnóstico, os valores do IPC-Ki-67 não apresentaram correlação 
significativa com a sobrevida. Conclusão: Com base nos nossos resultados, o IPC-Ki-67 pode ser utilizado para 
avaliação prognóstica em pacientes com osteossarcoma sem metástases ao diagnóstico.
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Background: Osteosarcoma is a relatively uncommon malignant neoplasm and little information has been
reported on its cell proliferation using Ki-67. Objectives: Evaluate histological, clinical and immunohis-
tochemical parameters using Ki-67 labeling index (LI), correlate one to another and with follow-up.
Material and method: Fifty-seven patients with available clinicopathological data submitted to the
study of cell proliferation as determined by Ki-67 expression measured by immunohistochemistry
(IHC) staining using formalin-fixed paraffin embedded sections. In each sample, positive cells were
quantified on at least a thousand nuclei and expressed as Ki-67 LI according to median value. Results
and discussion: Non-significant correlations were observed in metastatic and non-metastatic cases 
when variables as surgery, tumor size, death and relapse were compared with Ki-67 LI values (cut-off 
of 45%). In the group of non-metastatic cases there was a direct correlation between higher values of 
Ki-67 index and better overall survival. Metastatic patients overall survival curve and LI high and low
Ki-67 did not show significant differences. Conclusion: Based on our results the Ki-67 LI could be useful 
as a prognostic marker in patients without metastasis at diagnosis.
Osteosarcoma
Ki-67
Immunohistochemistry
Prognosis
420
MARINHO L. C. et al. Clinicopathologic study and Ki-67 proliferative marker evaluation in human osteosarcomas • J Bras Patol Med Lab • v. 41 • n. 6 • p. 419-24 • dezembro 2005
Introduction
Osteosarcoma (OS) is the most common primary 
malignant bone tumor in children and adolescents(21, 30, 31, 37).
Many published reports attempt to identify factors that may 
provide prognostic information on these tumors(17, 18, 22, 30, 36).
Studies were conducted both before and after the advent 
of adjuvant chemotherapy. All of them had methodologic 
variations that make them difficult to interpret and 
compare(20, 25, 29, 32, 35).
Factors that affect the prognosis of patients with 
osteosarcoma are age(5, 28), gender(3, 23), location of the 
lesion(9), size(2, 3, 22, 23, 24, 28, 30), histologic subtype(1, 10), grade 
and stage of the tumor(17, 18, 23).
Previous studies on cell kinetics in different human 
neoplasm have shown that cell proliferation can be 
associated with prognosis(16, 27, 34). The proliferative 
characteristics of tumor can be analyzed by a variety of 
methods, including mitosis count and the evaluation of the 
synthetic phase of the cell cycle by DNA analysis, thymidine 
incorporation or bromodeoxyuridine(15).
Ki-67 monoclonal antibody, specific for a nuclear antigen 
that is expressed throughout the cell cycle (late G1, S, G2 
and M), but absent in quiescent cells (G0)(7, 8), is proposed 
as an invaluable alternative. Ki-67 immunostaining allows 
an easy and rapid evaluation of tumor samples without the 
need for preliminary incubation with DNA precursors(14).
Although the nature of this antigen is still incompletely 
defined, the reliability of Ki-67 immunostaining as a 
proliferation marker has been investigated in different 
tumors(6, 12, 13).
In bone tumors, estimation of biologic behavior is an 
important clinical problem that is only partially solved 
by the morphologic parameters. For bone tumors only a 
few data have been reported about cell proliferation and 
prognosis(11, 19, 20, 25, 29, 32, 35).
Patients and methods
Between 1991 and 2000, we studied 57 patients newly 
diagnosed high-grade osteosarcoma of extremities at the 
Department of Pathology of Universidade Federal de São 
Paulo and treated at the Pediatric Oncology Institute (POI) 
of this institution. The characteristics of these patients are 
listed on Table 1.
The demographic and clinical variables examined were 
sex, tumor size, surgery and relapse. The pathologic size 
was determined at the time of operation based upon the 
greatest dimension of the macroscopic specimen. The 
follow-up period began at the date of diagnosis. Patients 
were followed until death or censored from this analysis 
at the time of their last visit to hospital. Follow-up ranged 
from 1 to 113,97 months (median: 29,4 months). Survival 
was recorded from time of diagnosis to death.
We have used the event metastases as a point to judge 
aggressiveness(17, 18, 22) and two groups were separated for 
the study of Ki-67 immunoexpression: patients with and 
those without metastases at diagnosis.
In 17 patients we could not retrieve blocks from files and 
two had only post-chemotherapy specimens. In an effort 
to avoid potential treatment-related effects on proliferation 
index, only pre-chemotherapy specimens were selected. In 
all cases, tissue blocks were taken from original biopsy prior 
to neoadjuvant chemotherapy. We studied 38 pediatric 
patients with high-grade osteosarcoma of extremities for 
Ki-67 expression.
Immunohistochemistry
The expression of Ki-67 (clone Ki-S5 Dako) was 
determined via standard immunohistochemical techniques 
on serial paraffin sections. All identifiable archival material 
(pre-chemotherapy specimens) from patients were retrieved 
from the Department of Pathology. The blocks were selected 
Clinical data of patients
Clinical features Patients (n)
Number of patients 57
Median age at diagnosis (years) 14,61
Sex (n = 57)
Male 37
Female 20
Size of tumor (n = 50)*
t 12cm 28
< 12cm 22
Surgery (n = 56)**
Limb salvage 32
Radical 24
Relapse (n = 56)**
No 51
Yes 5
Metastases at diagnosis (n = 57)
No 44
Yes 13
*Seven without information; **one refused surgery.
Table 1
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from the primary site in all cases. Bone specimens were 
decalcified with nitric acid (7.5%) and then washed in 
water for 30 minutes and immersed in sodium bicarbonate 
(5%) for 24 hours. Briefly 3-4µm formalin-fixed paraffin-
embedded tissue sections mounted on silane-coated slides 
were deparaffinized with xylene, passed through alcohol 
solutions and rinsed in deionized water. The sections 
were submitted to pressure cooker for five minutes after a 
treatment with 10mM citrate buffer. After that, the slides 
were rinsed in distilled water and endogenous peroxidase 
was inhibited with a 6% hydrogen peroxidase solution, in 
six incubation steps of five minutes each.
Diluted primary antibody was applied to sections, for 
18 hours at 4°C. After washing in phosphate-buffered saline 
(PBS) to remove antibody excess, the amplification step 
was carried out according to Dako Duet System protocol. 
The sections were incubated for 20 minutes at 37°C with 
biotinylated goat antimouse/rabbit immunoglobulins 
diluted 1:200 and then washed in PBS. The next incubation 
step employed 1:200 diluted streptavidin-biotin-peroxidase 
complex and color development was obtained with 60mg% 
diaminobenzidine plus 0.1% hydrogen peroxidase in PBS. 
After light counterstaining with Harry’s hematoxylin, slides 
were dehydrated in alcohol solutions and xylene, and 
permanently mounted.
The positive immunoreactions were counted through 
use of software (Imagem-Pro plus 3.0 version for Windows). 
In each sample, positive cells were quantified on at least a 
thousand cells and expressed as Ki-67 LI (labeling index). 
In those cases with multiple samples from the same 
lesion, the highest value ki-67 LI was considered the most 
representative for tumor proliferation and was used as the 
parameter for the analysis in this paper.
For those patients without metastases at diagnosis, high Ki-
67 LI was defined as greater than 46% of tumor cells showing 
nuclear immunoreactivity and low Ki-67 LI were those tumors 
with LI lower than 46%. For those with metastases at diagnosis 
we considered high Ki-67 LI higher than 45% and low Ki-67 
those LI lower than 45% (Figure 1).
Statistical analysis
Kaplan-Meier method and long-rank test were used to 
compare overall survival rates between patients with high 
and low Ki-67 index value.
The Fisher’s exact test and chi-square were used for clinical 
and IHC parameters. Cox regression and Kruskal-Walles test 
were used to compare index of Ki-67 and mortality.
Results
General aspects
Table 1 presents the clinical and pathological 
characteristics of 57 primary osteosarcoma patients included 
in the current study. Most of them were male.
From these patients, 44 (77.19%) were non-metastatic at 
diagnosis and 13 (22.81%) were metastatic at diagnosis.
In order to determine the significance of Ki-67 as an 
independent prognostic factor, patients were separated 
by Ki-67 expression considered high or low according 
to the index label expressed by the tumor cells and than 
correlated with clinical variables (sex, size of the tumor, 
surgery, relapse, and overall survival).
The median value of Ki-67 to patients without metastasis 
at diagnosis was 46% and those with metastases at 
diagnosis were 45%. This difference was not significant 
(p = 1) (Table 2). Distribution of results of immunostainings 
for Ki-67 considering the LI obtained for metastatic and 
non-metastatic patients is presented in Figure 2.
For those 44 grouped as non-metastatic at diagnosis, the 
Ki-67 LI was available in 26 (Table 2). The variables sex, surgery, 
tumor size and relapse were compared with Ki-67 high and low 
index label with non-significant correlation (Table 3). In the 
same group of non-metastatic patients there was significant 
difference between overall survival curves of those patients 
with Ki-67 LI high and low (p = 0.063) (Figure 3).
Among 13 metastatic patients, Ki-67 index label was 
available in 11. There were no significant correlation 
between Ki-67 LI high or low and variables sex, size of the 
tumor, surgery and relapse. The overall survival curve for 
those with high and low Ki-67 LI did not show significant 
difference (p = 0.43) (Figure 4).
Figure 1 – Nuclear Ki-67 immunoreactivity in osteosarcomas patients (arrowhead) 
(x 400)
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Expression of Ki-67 in metastatic and non-metastatic osteosarcomas in pediatric patients
Event metastases at diagnosis Low Ki-67 LI High Ki-67 LI p value
n         % n         %
No (n = 26) 13         50 13         50 1
Yes (n = 11) 6        54.5 5         45.45
Table 2
Expression of Ki-67 in non-metastatic osteosarcoma pre-chemotherapy patients
Variable Low Ki-67 LI High Ki-67 LI p value
n % n %
Sex (n = 44)
   Male (n = 24) 11 50 13 59.1 0.381
   Female (n = 20) 11 50 9 40.9
Surgery (n = 26)
   Limb salvage (n = 16) 6 37.5 10 62.5 0.226
   Radical (n = 10) 7 70 3 30
Size of tumor (n =21)
   < 12cm (n = 11) 4 36.36 7 63.64 0.198
t 12cm (n = 10) 7 70 3 30
Recurrence (n = 26)
   No (n = 22) 11 50 11 50 1
   Yes (n = 4) 2 50 2 50
Table 3
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Figure 2 – Distribution of ki-67 LI for metastatic and non-metastatic osteosarcomas Figure 3 – Overall survival: non-metastatic osteosarcomas
Figure 4 – Overall survival: metastatic osteosarcomas
Discussion
The monoclonal antibody Ki-67 exclusively reacts with 
a protein (Ki-67) expressed only during the proliferative 
phase of the cell cycle (late G1, G2, S and mitosis)(8). It was 
first described in 1983, by Gerdes et al.(7), to be used on 
fresh tissue. With the introduction of the MIB-1 antibody, 
a true Ki-67 equivalent, and a new antigen retrieval 
technique with the use of microwaves(26), immunostaining 
of formalin-fixed paraffin-embedded material was possible 
with a high reproducibility, equaling results obtained in fresh 
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material(14). In a number of publications Ki-67 has proven 
to be a reliable marker for measuring cell growth in human 
neoplasms (4, 27, 34).
In previous results regarding prognostic levels of Ki-67 
or MIB-1 in osteosarcomas, the mean values of Ki-67 LI vary 
because of different methodology. Vollmer et al.(33), in 1989, 
studied high malignant intramedullary osteosarcomas using 
the double indirect peroxidase method in frozen sections, 
and the count was made in ten fields, each holding about 
a hundred cells. The mean proliferative rate was 16.8%. 
Scotland et al.(25), in 1995, evaluated the Ki-67 expression 
by indirect immunofluorescence on cytologic specimens 
(single-cell suspensions). The percentage of positive cells 
was calculated for at least 5 hundred neoplastic cells 
and the mean index was 11.6%, calculated in primary, 
recurrent and metastatic osteosarcomas. After 1995, we 
had in literature studies of Ki-67 LI obtained in paraffin-
embedded tissue blocks. Oda et al.(19), Park and Park(20),
Stenzel et al.(29), Weiming et al.(35) and Hernandez-Rodriguez 
et al.(11) obtained in paraffin-embedded tissue blocks, using 
different methodologies in cell counting, different mean 
values of Ki-67 LI in osteosarcomas. In none of them the 
authors grouped metastatic and non-metastatic patients for 
analysis, and in none of them we have information about 
decalcification of bone tissues for obtaining slides sections 
for the study of Ki-67.
In our study the median proliferative rate was 46% for non-
metastatic patients and 45% for those metastatic at diagnosis. 
This difference was not significant (p = 1) (Table 2).
For those patients without metastasis at diagnosis 
there was statistic correlation between Ki-67 index and 
overall survival. Patients without metastasis at diagnosis 
with higher proliferative rate (> 46%) had better overall 
survival and those with lower proliferative index (d 46%) 
had worse overall survival (Figure 2). Our results suggest 
the existence of a positive correlation between tumor cell 
kinetics and effectiveness of preoperative chemotherapy. 
Scotland et al.(25) showed in a group of patients submitted to 
the same chemotherapy regimen a higher mean Ki-67 LI in 
good responders than in poor responders to chemotherapy. 
Hernandez-Rodriguez et al.(11) demonstrate that nuclear 
accumulation of Ki-67 in more than 50% of tumor cells 
in primary osteosarcoma is associated with increased 
pulmonary metastases and tumor mortality. Weiming et
al.(35) further show that nm23 expression parallels with the 
proliferative ability reflected by Ki-67 labeling is associated 
with early metastases. The isolated Ki-67 index showed no 
significant difference in metastases incidence in the same 
paper.
In our study of metastatic patients there were non-
significant correlation of values of Ki-67 and overall survival 
as showed by Weiming et al.(35). Hernandez-Rodrigues et
al.(11) observed overexpression of Ki-67 in those patients 
who developed pulmonary metastases.
In relation to the clinicopathological variables, we found 
no difference between size of the tumor, sex, surgery, 
relapse, and death and Ki-67 LI high or low in patients 
with or without metastasis. Hernandez-Rodriguez found 
no difference between age, sex, tumor size and histologic 
grade when comparing patients with high and low Ki-67 
index, but when Ki-67 index was associated with tumor 
size > 10cm patients had poor outcome. Weiming et al.(35)
showed correlation of Ki-67 index and tumor size and 
degree of differentiation.
With clinical data, radiologic size, grade and Ki-67 
index available, rational preoperative treatment planning, 
including entry into better follow-up for detection of 
pulmonary metastasis, could lead to post-operative 
observation and close examination. Detection of Ki-67 may 
then improve overall survival of patients together with new 
treatments.
Conclusion
Based on our results, the Ki-67 LI could be used as a 
prognostic marker in patients with osteosarcoma without 
metastasis at diagnosis.
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